Characterization of Innate Immune Responses to MF59 Adjuvanted H5N1 Vaccine Compared to Non-adjuvanted H5N1 Vaccine.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs AS03A (Primary) ; Influenza A virus vaccine-H5N1; MF 59
- Indications Influenza A virus H5N1 subtype
- Focus Pharmacodynamics
- 26 Feb 2019 Biomarkers information updated
- 20 Dec 2013 Planned number of patients changed from 55 to 60 as reported by ClinicalTrials.gov.
- 20 Dec 2013 Planned end date changed from 1 Mar 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.